the Thank in XXXX. all you, of thank a in Mariann, third today. and quarter quarter the a slight our reported Net revenue you XXXX the $XX.X and in XXXX as the as license Today, reported joining from for reported sales from representing and $XX.X call includes second revenue QX in our million. for quarter of royalty from NERLYNX Puma million Total fees were U.S. of XXXX, of NERLYNX sales of well decrease increase million sublicensees. second million $XX.X net net $XX.X sales total the
the quarter a of result XXXX, During COVID-XX continue as third experience the to we of on challenges brought pandemic.
the NERLYNX’s royalty and of with Our third key Maximo of financial a more quarter the our of XXXX. Ludwig details some then follow commercial also with results will of begin activities. highlights for Jeff will of I on highlights will million. of the third quarter of the $X.X included components review statements quarter, provide Nougues revenue the
to we These the improve to Annals the several neratinib of trial to dose of results the drug anti-diarrheal improved the aware, the the can use reduce prophylactic in neratinib adjuvant results were variety tolerability published increase diarrhea neratinib-related publication breast X tolerability CONTROL significantly as of an to a from Grade of help journal, are use anti-diarrheal As referred including of using issue be of investors Interim drugs We this and incidence can will strategies. trial drug. of in the demonstrated with believe be diarrhea the the or the improve ongoing the the the that Puma XXXX, increase be Oncology. incidence may escalation techniques, wide reduced the further prophylactic fourth these September of and in are additional awareness early using quarter of CONTROL the drug. of cancer presented awareness help tolerability which investigating the of has results techniques the of further setting, the from HERX-positive of of the We where anticipate extended trial, these techniques. medical trial will that
HR-positive of Breast results Trial In NERLYNX Cancer. patient population. addition, ExteNET stage Phase announced awareness October, benefits will the its the journal, this from published believe that also early that Clinical HERX-positive the We cancer early in increase population breast in we X the and neratinib were efficacy in our in of this
arm Stage Stage And a patients respond, further respond, the If to are no the enrolled. has then the ongoing cancer have fulvestrant closed for expanded to an patients will I such study will arm cancers a trial. or be plus more As in in investors additional initial plus design, combination or if arm patients the during HERX of patient If breast to the the closed of SUMMIT either I. as X-stage is trastuzumab. that trial and trial Under Puma will XX who was also up respond, mutation SUMMIT expanded neratinib patients. given referred further enrollment. in patients in enrollment. amended be enroll of fulvestrant arm HERX-mutated If has modified be that XXXX, The that each fulvestrant HERX-negative plus than neratinib the arm less arm basket aware, are Simon trastuzumab receive ER-positive, to in than more early will patients the arm four seven four respond, expanded first alone, randomized patients
the the increase quarter month of on SUMMIT increase earnings trial the negatively continue slightly enrollment in second did impacted into call, to quarter to third of our and was reported in COVID-XX XXXX QX in Enrollment continue As pandemic. October. by the
X-stage the half occur XXXX. of Simon into Assuming for initial we anticipate the breast the will of continues, the cohorts HR-positive this first in trend cancer enrollment trial that
we we of occur want recognize the be that any later could or continue this this uncertainty to year COVID-XX. year. should initial potential additional in of for with to schedule And COVID-XX impacted breast the meeting associated potential approval. early the the cohorts, the HR-positive discuss also X-stage next pre-NDA find the we received accelerated FDA results by Simon However, with from recognize Once wave cancer
anticipate that the duct mutations with also neratinib with XXXX, We will were patients reporting of we of cancer the which cohort with II first data trial, bile HERX in the from in quarter treated Stage SUMMIT monotherapy. be
with cancer, XX with cohort a amended monotherapy. In were mutations, addition, treated was EGFR cell include to new with be included patients of non-small who the lung exon patients Simon recently to most cohort treated. trial neratinib This
efficacy today the are of We preliminary presenting from patients. this cohort data
slide, The the mutations lung Exon XX preclinical mutations As XX EGF has you detected exon cancer. are in mutations comprise data approximately lung can mutations in EGFR on rare the cancer. X% see of XX or of exon this exon appear several sensitive EGFR kinase against TKIs XX that EGFR-directed data The tyrosine demonstrated mutations mutations. to on the preclinical inhibitors neratinib. be to EGFR efficacy slide shows
see Based tested patients arm cancer with Exxon there as a up in was lung this XX of patients study neratinib EGFR-directed new in cancer. potency of If during than expanded strongest be And weeks. further with was that were trial will in had who receive PFS trial, can there clinical patients. the arm Simon from in preclinical and first GXXXX XX.X open the we endometrial the the patients To-date additional the arm treatments more TKIs Exxon with initially median of closed in to the These trial, in treated XX four Clinical this four The Oncology. data, the compared would amended with median If the patients SUMMIT XX Exxon lung date. two patients expanded if four we less will patient patients patients with trial, mutations enrolled than enrolled where to trial for been muted stage neratinib in in response more cohort four all XX the have mutations, for designed be to respond, three responded, mutations, checkpoint arm cancer. EGFR lung enrolled enrollments. enrolled inhibitors. with appears the mutation. the we the treatment a the in or expanded respond, patients non-small including was monotherapy. a would on be tested. have other prior cell patients further Exxon setting, Journal the slide, chemotherapy seven to you X. experienced As previously against which X-stage Neratinib trial patients This enrollments. In Of cohort. and responded, a metastatic data Phase the Stage These If published close one were to no of cohort patients XX a XXXX XX on partial this X the in was
treatment, rate Importantly, as there The the was response for months. a these TKIs XX% and was TKI received were patients like demonstrates included this patients well inhibitor, the was and TKI osimertinib showed afatinib. XX% confirmed the of the duration PFS tyrosine like six responses which erlotinib, responses. being in clinical overall reversible responses dasatinib received EGFR prior irreversible preliminary trial XX four of or X.X XX% trial kinase best received The prior data or X.X treatment benefit and these with as with the XX response inhibitors treatment, EGFR an patients In partial who cohort who as efficacy from of median median EGFR-directed XX who prior months. that patients partial
you can and plot the You plot see on the see waterfall left. the slide, the on on score the right
had in number of XX as the you mutations EXXXX, patients complex groups plots, Exxon treatment, the can these single responses of GXXX a either was all complex the and which XX see GXXXX TKI as the had Of in were who excuse from single combination mutation SXXXI, had either either prior received mutation, and/or with or seen me, EGFR EGFR of patients mutation a or patients. – the present TXXXM. patients both As
experiencing As cases that the any data treated data or the were common for and the four Grade patients monotherapy. most XX of of event were of trial diarrhea. no was are patients or grade higher there X the neratinib Safety the the patients still August trial, demonstrated from patients being cutoff, diarrhea, five there diarrhea. in XX.X% with There adverse
afatinib, drug discontinued Exxon its permanently the label commercially XX hold, closer, in patient Looking at put or the is that X approved required diarrhea, mutations Gilotrif. patients neratinib is diarrhea. only is context dose No X one FDA due this who patients data a known To diarrhea. had patient into had five reduction, of which Grade diarrhea, and Grade that four data dose to diarrhea has or as experienced this
treated been of previously As an afatinib you have overall with can see patients the response slide in an XX.X%. rate demonstrated EGFR on TKI who has
Simon Although compares we it the met, has been second The is in the of continuing cohort cell that the predetermined Exxon patients. Enrollment first SUMMIT criteria patients. early, stage and second data. of the favorably to stage a believe lung criteria for mutated cancer both of total now stage XX afatinib for non-small X-stage to XX and with is neratinib this EGFR data success this up
tyrosine data scheduling additional non-small approval with this We We lung XX for a previously EGFR during in a the in accelerated first anticipate XXXX. EGFR meeting updated further XXXX. in potential treated cancer of cell discuss from who Exxon sometime been the expect with the an inhibitor patients have mutated conference FDA medical to with half to kinase of cohort patients present
on now metastatic pediatric glioblastoma. with call Puma’s mets, the its amplified the our breast mutated over different early tumor the on tumors HER-X XX, study its Commercial In tumors, types. quarter. research in Chief including HERX-positive to in role to view to will and plans stage Network, of collaborate the for focus National turn commercial and various trial other Comprehensive announced These will explore the Officer neratinib projects cancer, cancer EGFR Jeff Cancer Puma of brain October Ludwig, with in projects, to those SUMMIT during addition progress treatment to I performance
